Tait R C, Sefcick A
Department of Haematology, Southern General Hospital, Glasgow.
Br J Haematol. 1998 Jun;101(3):450-4. doi: 10.1046/j.1365-2141.1998.00716.x.
Currently available protocols for induction of warfarin anticoagulation employ initial doses of 10 mg and are best suited to in-patient use. However, with the increasing number of elderly patients with atrial fibrillation requiring anticoagulation, there is a need for a less intense regimen which could be used for out-patients. We have established such a regimen and report on its prospective evaluation in 3 7 patients referred for out-patient initiation of warfarin, and a non-randomized comparison with 37 in-patients, with similar diagnoses, commenced on a traditional warfarin protocol. After exclusion of five patients on amiodarone, all of whom experienced supratherapeutic International Normalized Ratio (INR) results, the new out-patient regimen, employing an initial 5 mg dose, resulted in a lower maximum INR during the first 21 d therapy (median 2.9 v 4.0; P = 0.0001) and fewer INRs >4.5 (2/36 v 9/33) compared to the traditional 10 mg regimen. Time to reach stable anticoagulation was similar with each regimen; however, the 5 mg regimen gave a more accurate prediction of maintenance dose (correlation coefficient for predicted versus actual maintenance dose, r = 0.985). In comparison to a traditional 10 mg protocol, the proposed 5 mg warfarin induction regimen proved both safer and more reliable for initiation of prophylactic anticoagulation in patients with atrial fibrillation.
目前可用的华法林抗凝诱导方案采用初始剂量10毫克,最适合住院患者使用。然而,随着需要抗凝治疗的老年房颤患者数量的增加,需要一种强度较低的方案用于门诊患者。我们已经建立了这样一种方案,并报告了对37例因门诊启动华法林治疗而转诊患者的前瞻性评估,以及与37例诊断相似、按照传统华法林方案开始治疗的住院患者进行的非随机比较。在排除5例使用胺碘酮的患者后(所有这些患者的国际标准化比值(INR)结果均高于治疗范围),采用初始5毫克剂量的新门诊方案在治疗的前21天内导致的最高INR较低(中位数2.9对4.0;P = 0.0001),且INR>4.5的情况较少(2/36对9/33),与传统的10毫克方案相比。达到稳定抗凝的时间在两种方案中相似;然而,5毫克方案对维持剂量的预测更准确(预测维持剂量与实际维持剂量的相关系数,r = 0.985)。与传统的10毫克方案相比,所提出的5毫克华法林诱导方案在房颤患者预防性抗凝启动方面被证明既更安全又更可靠。